{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T22:38:29Z","timestamp":1785883109191,"version":"3.56.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.clml.2025.05.016","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T19:46:48Z","timestamp":1747856808000},"page":"e685-e695.e17","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Delphi Survey on Measurable Residual Disease in Multiple Myeloma: Prevailing Practices and the Way Forward in India"],"prefix":"10.1016","volume":"25","author":[{"given":"Smeeta","family":"Gajendra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanima","family":"Dwivedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0851-886X","authenticated-orcid":false,"given":"Karthik","family":"Bommannan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjit Kumar","family":"Sahoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7025-6210","authenticated-orcid":false,"given":"Nupur","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant","family":"Tembhare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaliqur","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Gogia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raja","family":"Pramanik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin","family":"Dayal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6041-1512","authenticated-orcid":false,"given":"Rakhee","family":"Kar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyoti","family":"Kotwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Sanjeev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asish","family":"Rath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diksha","family":"Dev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4793-6829","authenticated-orcid":false,"given":"Ganesh Kumar","family":"Viswanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man Updesh Singh","family":"Sachdeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9885-1625","authenticated-orcid":false,"given":"Mukul","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devasis","family":"Panda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2626-4154","authenticated-orcid":false,"given":"Sreejesh","family":"Sreedharanunni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uday","family":"Yanamandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun Kumar","family":"Arunachalam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhausaheb","family":"Bagal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabhat S.","family":"Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Handoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9999-3425","authenticated-orcid":false,"given":"Sanjeev Kumar","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer","family":"Bakhshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2627-5814","authenticated-orcid":false,"given":"Atul","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak Kumar","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankaj","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9210-2500","authenticated-orcid":false,"given":"Lalit","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5364-4086","authenticated-orcid":false,"given":"Ritu","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2025.05.016_bib0001","article-title":"Minimal residual disease in multiple myeloma","author":"Moukalled","year":"2024","journal-title":"Presse Med"},{"issue":"18","key":"10.1016\/j.clml.2025.05.016_bib0002","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1182\/blood.2023020284","article-title":"Potential future direction of measurable residual disease evaluation in multiple myeloma","volume":"142","author":"Mohty","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.05.016_bib0003","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.801851","article-title":"Minimal residual disease assessment in multiple myeloma patients: minimal disease with maximal implications","volume":"11","author":"Charalampous","year":"2022","journal-title":"Front Oncol"},{"issue":"5","key":"10.1016\/j.clml.2025.05.016_bib0004","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1309\/AJCP1GYI7EHQYUYK","article-title":"Flow cytometric immunophenotyping and minimal residual disease analysis in multiple myeloma","volume":"132","author":"Gupta","year":"2009","journal-title":"Am J Clin Pathol"},{"issue":"2","key":"10.1016\/j.clml.2025.05.016_bib0005","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41408-021-00418-2","article-title":"Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation","volume":"11","author":"Derman","year":"2021","journal-title":"Blood Cancer J"},{"issue":"6","key":"10.1016\/j.clml.2025.05.016_bib0006","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1158\/1078-0432.CCR-23-2767","article-title":"Monitoring minimal residual disease in patients with multiple myeloma by targeted tracking serum M-protein using mass spectrometry (EasyM)","volume":"30","author":"Fan","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2025.05.016_bib0007","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1073479","article-title":"MALDI-TOF-MS for rapid screening analysis of M-protein in serum","volume":"12","author":"Li","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.clml.2025.05.016_bib0008","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1021\/jasms.3c00166","article-title":"Improved screening of monoclonal gammopathy patients by MALDI-TOF mass spectrometry","volume":"34","author":"Pe\u010dinka","year":"2023","journal-title":"J Am Soc Mass Spectrom"},{"issue":"4","key":"10.1016\/j.clml.2025.05.016_bib0009","doi-asserted-by":"crossref","first-page":"485","DOI":"10.5858\/arpa.2020-0457-OA","article-title":"Assessment of clonotypic rearrangements and minimal residual disease in lymphoid malignancies","volume":"146","author":"Hussaini","year":"2022","journal-title":"Arch Pathol Lab Med"},{"issue":"23","key":"10.1016\/j.clml.2025.05.016_bib0010","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1182\/blood-2014-02-556746","article-title":"Next-generation sequencing of peripheral B-lineage cells pinpoints the circulating clonotypic cell pool in multiple myeloma","volume":"123","author":"Thiele","year":"2014","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clml.2025.05.016_bib0011","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1080\/10428194.2017.1386304","article-title":"Minimal residual disease analysis in myeloma - when, why and where","volume":"59","author":"Yanamandra","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2025.05.016_bib0012","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.820605","article-title":"The utility of euro flow MRD assessment in real-world multiple myeloma practice","volume":"12","author":"Turner","year":"2022","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.clml.2025.05.016_bib0013","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/ajcp\/aqac129","article-title":"Graded depth of response and neoplastic plasma cell index as indicators of survival outcomes in patients with multiple myeloma following autologous stem cell transplant","volume":"159","author":"Das","year":"2023","journal-title":"Am J Clin Pathol"},{"issue":"5","key":"10.1016\/j.clml.2025.05.016_bib0014","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1080\/10428194.2016.1228930","article-title":"Minimal residual disease evaluation in autologous stem cell transplantation recipients with multiple myeloma","volume":"58","author":"Gupta","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.clml.2025.05.016_bib0015","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/cyto.b.22053","article-title":"Evaluation of multiple myeloma measurable residual disease by high sensitivity flow cytometry: an international harmonized approach for data analysis","volume":"102","author":"Soh","year":"2022","journal-title":"Cytometry B ClinCytom"},{"issue":"2","key":"10.1016\/j.clml.2025.05.016_bib0016","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/ijlh.13992","article-title":"Utility of CD229 as a novel marker in measurable residual disease assessment in multiple myeloma-an evidence-based approach","volume":"45","author":"Rai","year":"2023","journal-title":"Int J Lab Hematol"},{"issue":"6","key":"10.1016\/j.clml.2025.05.016_bib0017","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.4103\/jcrt.JCRT_1027_19","article-title":"Utility and feasibility of a six-color multiparametric flow cytometry for measurable residual disease analysis in plasma cell myeloma in resource-limited settings with 5-year survival data","volume":"17","author":"Sharma","year":"2021","journal-title":"J Cancer Res Ther"},{"issue":"4","key":"10.1016\/j.clml.2025.05.016_bib0018","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.1002\/hem3.63","article-title":"Circulating tumor plasma cells and peripheral blood measurable residual disease assessment in multiple myeloma patients not planned for upfront transplant","volume":"8","author":"Tembhare","year":"2024","journal-title":"Hemasphere"},{"issue":"9","key":"10.1016\/j.clml.2025.05.016_bib0019","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1038\/s41409-023-02017-0","article-title":"Dual assessment with multiparameter flow cytometry and 18F-FDG PET\/CT scan provides enhanced prediction of measurable residual disease after autologous haemopoietic stem cell transplant in myeloma-a prospective study","volume":"58","author":"Mookerjee","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.clml.2025.05.016_bib0020","doi-asserted-by":"crossref","first-page":"116","DOI":"10.5662\/wjm.v11.i4.116","article-title":"Delphi methodology in healthcare research: how to decide its appropriateness","volume":"11","author":"Nasa","year":"2021","journal-title":"World J Methodol"},{"issue":"4","key":"10.1016\/j.clml.2025.05.016_bib0021","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1046\/j.1365-2648.2000.t01-1-01567.x","article-title":"Research guidelines for the Delphi survey technique","volume":"32","author":"Hasson","year":"2000","journal-title":"J Adv Nurs"},{"key":"10.1016\/j.clml.2025.05.016_bib0022","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.zefq.2022.04.025","article-title":"Reporting guidelines for Delphi techniques in health sciences: a methodological review","volume":"172","author":"Spranger","year":"2022","journal-title":"Z Evid Fortbild Qual Gesundhwes"},{"key":"10.1016\/j.clml.2025.05.016_bib0023","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3389\/fpubh.2020.00457","article-title":"Delphi technique in health sciences: a map","volume":"8","author":"Niederberger","year":"2020","journal-title":"Front Public Health"},{"issue":"6","key":"10.1016\/j.clml.2025.05.016_bib0024","article-title":"Immunophenotypic profile and measurable residual disease monitoring in multiple myeloma: a prospective study from a tertiary care centre in southern India","volume":"16","author":"Sathya","year":"2024","journal-title":"Cureus"},{"issue":"3","key":"10.1016\/j.clml.2025.05.016_bib0025","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/cyto.b.22068","article-title":"Relevance of polyclonal plasma cells and post-therapy immunomodulation in measurable residual disease assessment in multiple myeloma","volume":"102","author":"Das","year":"2022","journal-title":"Cytometry B ClinCytom"},{"issue":"5","key":"10.1016\/j.clml.2025.05.016_bib0026","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.3324\/haematol.2020.267831","article-title":"Standardization of flow cytometric minimal residual disease assessment in international clinical trials - a feasibility study from the European myeloma network","volume":"106","author":"Hofste Op Bruinink","year":"2020","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.clml.2025.05.016_bib0027","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1177\/0269216317690685","article-title":"Guidance on conducting and reporting Delphi studies (CREDES) in palliative care: recommendations based on a methodological systematic review","volume":"31","author":"J\u00fcnger","year":"2017","journal-title":"Palliat Med"},{"issue":"9","key":"10.1016\/j.clml.2025.05.016_bib0028","doi-asserted-by":"crossref","first-page":"e942","DOI":"10.1097\/HS9.0000000000000942","article-title":"Measurable residual disease testing in multiple myeloma routine clinical practice: a modified Delphi study","volume":"7","author":"Ramasamy","year":"2023","journal-title":"Hemasphere"},{"issue":"2","key":"10.1016\/j.clml.2025.05.016_bib0029","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1200\/JCO.24.00635","article-title":"Minimally invasive assessment of peripheral residual disease during maintenance or observation in transplant-eligible patients with multiple myeloma","volume":"43","author":"Lasa","year":"2024","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.clml.2025.05.016_bib0030","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1182\/blood.2019002610","article-title":"Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy","volume":"134","author":"Sanoja-Flores","year":"2019","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clml.2025.05.016_bib0031","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"23","key":"10.1016\/j.clml.2025.05.016_bib0032","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1182\/blood.2022016170","article-title":"MRD in multiple myeloma: does CR really matter?","volume":"140","author":"Paiva","year":"2022","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.clml.2025.05.016_bib0033","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/cyto.a.24904","article-title":"Overcoming fixation and permeabilization challenges in flow cytometry by optical barcoding and multi-pass acquisition","volume":"105","author":"Fahlberg","year":"2024","journal-title":"Cytometry A"},{"issue":"3","key":"10.1016\/j.clml.2025.05.016_bib0034","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1182\/blood-2016-07-726307","article-title":"EuroFlow Consortium. Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia","volume":"129","author":"Theunissen","year":"2017","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.clml.2025.05.016_bib0035","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.05.016_bib0036","doi-asserted-by":"crossref","first-page":"112520","DOI":"10.1016\/j.jim.2018.09.008","article-title":"Frequent issues and lessons learned from EuroFlow QA","volume":"475","author":"Kalina","year":"2019","journal-title":"J Immunol Methods"},{"issue":"2","key":"10.1016\/j.clml.2025.05.016_bib0037","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/cyto.a.22581","article-title":"Quality assessment program for EuroFlow protocols: summary results of four-year (2010\u20132013) quality assurance rounds","volume":"87","author":"Kalina","year":"2015","journal-title":"Cytometry A"},{"issue":"10","key":"10.1016\/j.clml.2025.05.016_bib0038","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1038\/leu.2017.29","article-title":"Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma","volume":"31","author":"Flores-Montero","year":"2017","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.clml.2025.05.016_bib0039","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/cyto.b.21228","article-title":"Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting","volume":"90","author":"Arroz","year":"2016","journal-title":"Cytometry B ClinCytom"},{"issue":"1","key":"10.1016\/j.clml.2025.05.016_bib0040","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/cyto.b.21249","article-title":"Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition","volume":"90","author":"Stetler-Stevenson","year":"2016","journal-title":"Cytometry B Clin Cytom"},{"issue":"1","key":"10.1016\/j.clml.2025.05.016_bib0041","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13045-020-00911-4","article-title":"Measurable residual disease in multiple myeloma: ready for clinical practice?","volume":"13","author":"Burgos","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"9","key":"10.1016\/j.clml.2025.05.016_bib0042","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1182\/blood.2024024041","article-title":"Mass spectrometry-based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma","volume":"144","author":"Kubicki","year":"2024","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2025.05.016_bib0043","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1080\/10408363.2023.2209652","article-title":"Advances in minimal residual disease monitoring in multiple myeloma","volume":"60","author":"Wijnands","year":"2023","journal-title":"Crit Rev Clin Lab Sci"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025001806?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025001806?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T11:19:07Z","timestamp":1762600747000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025001806"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":43,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S2152265025001806"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.05.016","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Delphi Survey on Measurable Residual Disease in Multiple Myeloma: Prevailing Practices and the Way Forward in India","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.05.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}